Diagnostic test measuring antibodies to NR2 to assess risk of ischemic stroke and cerebral ischemia.
Manufactured by
Rapid Technology LLC
Russia
Rapid Technology LLC, operating as DRD Biotech, was founded in 2014 in the Republic of Buryatia, Russia. The company develops and manufactures rapid diagnostic devices for laboratories and point-of-care testing applications. DRD Biotech specializes in rapid blood tests based on innovative biotechnology and information technology solutions. The company focuses on developing affordable rapid diagnostics for healthcare systems. DRD Biotech's product development centres on rapid tests for diagnosing brain damage conditions, particularly ischemic stroke and traumatic brain injury, using key biomarkers. The company partners with research centres and medical companies across Russia, USA, and Europe to support development and distribution of diagnostic products.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
GenSure Biotech Inc.
China · 1 relevant product
ABCDx
Spain · 2 relevant products
CEPALAB
Brazil · 1 relevant product
64 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →10 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
3 of 92 closest product alternatives
GenSure Biotech Inc. · China
Diagnostic test kit for measurement of biomarkers associated with cerebrovascular disease and stroke risk. Facilitates assessment of neurological and cerebrovascular health status.
ABCDx · Spain
A rapid biochemical test that differentiates between ischemic stroke and intracranial hemorrhage within the first 4 hours from symptom onset. The test uses a combination of biomarkers to provide accurate diagnosis for stroke subtype determination, enabling rapid decision-making at point-of-care settings including ambulances and primary hospitals. This allows for timely initiation of specific treatment protocols such as reperfusion therapies.
CEPALAB · Brazil
A diagnostic test for detection of dengue NS1 antigen in serum samples.
89 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products